PMID- 37975226
OWN - NLM
STAT- MEDLINE
DCOM- 20231216
LR  - 20240124
IS  - 1744-8360 (Electronic)
IS  - 1473-7175 (Linking)
VI  - 23
IP  - 12
DP  - 2023 Jul-Dec
TI  - Advances in amyloid-targeting monoclonal antibodies for Alzheimer's disease: 
      clinical and public health issues.
PG  - 1113-1129
LID - 10.1080/14737175.2023.2284305 [doi]
AB  - INTRODUCTION: Alzheimer's disease (AD) is a major global public health challenge. 
      To date, no treatments have been shown to stop the underlying pathological 
      processes. The cerebral accumulation of amyloid-beta (Ab) is still considered as 
      the primum movens of AD and disease-modifying treatments targeting Ab are 
      reaching - or have already reached - clinical practice. AREAS COVERED: The 
      authors explore the main advancements from Abeta-targeting monoclonal antibodies 
      (mAbs) for the treatment of AD. From a public health perspective, they address 
      ethically relevant issues such as the benevolence and non-maleficence principles. 
      They report on the potential biological and clinical benefits of these drugs, 
      discussing minimal clinically important differences (MCID) and other relevant 
      outcomes. They examine the short- and long-term effects of amyloid-related 
      imaging abnormalities (ARIA), and explore the differences between eligibility 
      criteria in clinical trials, appropriate use recommendations, and prescribing 
      information content. In doing so, they contextualize the discussion on the 
      disagreements among different regulatory authorities. EXPERT OPINION: Although 
      anti-beta-amyloid monoclonal antibodies may be effective in selected scenarios, 
      non-negligible knowledge gaps and implementation limits persist. Overcoming these 
      gaps can no longer be postponed if we are to ensure the principles of Quality of 
      Care for patients with cognitive impairment who would be eligible for this class 
      of drugs.
FAU - Salemme, Simone
AU  - Salemme S
AD  - Department of Biomedical, Metabolic, and Neural Sciences, University of Modena 
      and Reggio Emilia, Modena, Italy.
FAU - Ancidoni, Antonio
AU  - Ancidoni A
AD  - National Centre for Disease Prevention and Health Promotion, Italian National 
      Institute of Health, Rome, Italy.
AD  - Department of Public Health and Infectious Diseases, Sapienza University, Rome, 
      Italy.
FAU - Locuratolo, Nicoletta
AU  - Locuratolo N
AD  - National Centre for Disease Prevention and Health Promotion, Italian National 
      Institute of Health, Rome, Italy.
FAU - Piscopo, Paola
AU  - Piscopo P
AD  - Department of Neuroscience, Italian National Institute of Health, Rome, Italy.
FAU - Lacorte, Eleonora
AU  - Lacorte E
AD  - National Centre for Disease Prevention and Health Promotion, Italian National 
      Institute of Health, Rome, Italy.
FAU - Canevelli, Marco
AU  - Canevelli M
AD  - National Centre for Disease Prevention and Health Promotion, Italian National 
      Institute of Health, Rome, Italy.
AD  - Department of Human Neuroscience, "Sapienza" University, Rome, Italy.
FAU - Vanacore, Nicola
AU  - Vanacore N
AD  - National Centre for Disease Prevention and Health Promotion, Italian National 
      Institute of Health, Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231215
PL  - England
TA  - Expert Rev Neurother
JT  - Expert review of neurotherapeutics
JID - 101129944
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Amyloid beta-Peptides)
SB  - IM
MH  - Humans
MH  - *Alzheimer Disease/drug therapy
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Public Health
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Amyloid beta-Peptides
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - amyloid, monoclonal antibodies
OT  - efficacy
OT  - public health
OT  - safety
EDAT- 2023/11/17 15:30
MHDA- 2023/12/17 09:44
CRDT- 2023/11/17 05:27
PHST- 2023/12/17 09:44 [medline]
PHST- 2023/11/17 15:30 [pubmed]
PHST- 2023/11/17 05:27 [entrez]
AID - 10.1080/14737175.2023.2284305 [doi]
PST - ppublish
SO  - Expert Rev Neurother. 2023 Jul-Dec;23(12):1113-1129. doi: 
      10.1080/14737175.2023.2284305. Epub 2023 Dec 15.